Please assess the completion status of the following clinical trial:

Trial Title: Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Decompensated Cirrhosis of liver.~Exclusion Criteria:~* Acute on chronic liver failure~* Spleen diameter of larger than 180 mm~* Diagnosis of concomitant hepatocellular carcinoma or other active malignancy~* Upper gastrointestinal bleed due to portal hypertension in the previous 7 days~* Recent episode of portal vein thrombosis~* Severe renal dysfunction creatinine (\>1.5mg/dl)~* Severe cardiac dysfunction~* Uncontrolled diabetes or diabetic retinopathy~* Acute infection or disseminate intravascular coagulation~* Active alcohol abuse in last 3months~* Known hypersensitivity to G-CSF and GH~* Human immunodeficiency virus seropositivity~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- standard medical therapy (Type: ACTIVE_COMPARATOR): Standard medical therapy
- G-CSF (Type: ACTIVE_COMPARATOR): Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
- G-CSF plus growth hormone (Type: ACTIVE_COMPARATOR): Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).